Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7% – Should You Buy?

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) traded up 3.7% during trading on Friday . The company traded as high as $1.98 and last traded at $1.96. 11,208 shares were traded during mid-day trading, a decline of 98% from the average session volume of 565,195 shares. The stock had previously closed at $1.89.

Analyst Upgrades and Downgrades

IPHA has been the topic of a number of analyst reports. HC Wainwright set a $5.00 price target on shares of Innate Pharma and gave the company a “buy” rating in a research report on Wednesday, October 29th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Innate Pharma in a research note on Wednesday, October 29th. Leerink Partnrs cut shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 18th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down previously from $10.00) on shares of Innate Pharma in a report on Thursday, September 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Innate Pharma Stock Up 3.7%

The company’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $2.00.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.